HUE051020T2 - A ceramid szintjei a fertõzések kezelésében és megelõzésében - Google Patents

A ceramid szintjei a fertõzések kezelésében és megelõzésében

Info

Publication number
HUE051020T2
HUE051020T2 HUE13797635A HUE13797635A HUE051020T2 HU E051020 T2 HUE051020 T2 HU E051020T2 HU E13797635 A HUE13797635 A HU E13797635A HU E13797635 A HUE13797635 A HU E13797635A HU E051020 T2 HUE051020 T2 HU E051020T2
Authority
HU
Hungary
Prior art keywords
infections
prevention
treatment
ceramide levels
ceramide
Prior art date
Application number
HUE13797635A
Other languages
English (en)
Inventor
Edward Schuchman
Erich Gulbins
Anthony Futerman
Yael Pewzner-Jung
Original Assignee
Icahn School Med Mount Sinai
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Yeda Res & Dev filed Critical Icahn School Med Mount Sinai
Publication of HUE051020T2 publication Critical patent/HUE051020T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13797635A 2012-06-01 2013-05-31 A ceramid szintjei a fertõzések kezelésében és megelõzésében HUE051020T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261654519P 2012-06-01 2012-06-01

Publications (1)

Publication Number Publication Date
HUE051020T2 true HUE051020T2 (hu) 2021-01-28

Family

ID=49673925

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13797635A HUE051020T2 (hu) 2012-06-01 2013-05-31 A ceramid szintjei a fertõzések kezelésében és megelõzésében

Country Status (14)

Country Link
US (4) US9492514B2 (hu)
EP (2) EP3679923B1 (hu)
JP (4) JP6369814B2 (hu)
CN (2) CN104582770B (hu)
CA (1) CA2874146C (hu)
DK (1) DK2854910T3 (hu)
ES (2) ES2786128T3 (hu)
HR (1) HRP20200661T1 (hu)
HU (1) HUE051020T2 (hu)
LT (1) LT2854910T (hu)
PL (1) PL2854910T3 (hu)
PT (1) PT2854910T (hu)
SI (1) SI2854910T1 (hu)
WO (1) WO2013181530A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
SI3219705T1 (sl) 2005-12-28 2020-08-31 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki amorfne oblike N-(2,4-bis(1,1-dimetiletil)-5- hidroksifenil)-1,4-dihidro-4-oksokinolin-3-karboksamid
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
ES2786128T3 (es) 2012-06-01 2020-10-08 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MX2015012471A (es) 2013-03-14 2016-08-03 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
US10023918B2 (en) 2013-03-14 2018-07-17 University Of Ottawa Methods for the diagnosis and treatment of inflammatory bowel disease
EP3201622A4 (en) 2014-10-03 2018-05-30 The University of Ottawa Markers for inflammatory bowel disease
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JOP20190164B1 (ar) * 2017-01-13 2023-09-17 Icahn School Med Mount Sinai تركيبات وطرق لعلاج داء فاربر
WO2022190064A1 (en) * 2021-03-12 2022-09-15 Vexo Pharmaceuticals Dmcc Methods for identifying subjects with betacoronavirus infections who are at risk of acute respiratory syndrome and methods for the treatment of same

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
CH585793A5 (hu) 1974-02-01 1977-03-15 Nestle Sa
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
JPS5322158B2 (hu) 1974-05-02 1978-07-06
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1990011353A1 (en) 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
HUT72469A (en) 1992-12-30 1996-04-29 Revis Anticaries compositions
AU689786B2 (en) 1993-06-30 1998-04-09 Genentech Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE333893T1 (de) 1997-10-29 2006-08-15 Genzyme Corp Gentherapie für gaucher-krankheit
EP1064026A4 (en) 1998-03-10 2003-04-09 Univ Pennsylvania STRENGTHENING INTRA-CELLULAR ADMINISTRATION AND TARGETING SPECIFIC TISSUE OF MEDICINES AND GENES
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
WO2001026678A1 (en) 1999-10-13 2001-04-19 Yeda Research And Development Co. Ltd. Short segments of dap-kinase
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
AU2001253181A1 (en) 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
CA2473360A1 (en) 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN105316405A (zh) 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
WO2006113289A2 (en) 2005-04-19 2006-10-26 Vermillion, Inc. Saposin d and fam3c are biomarkers for alzheimer's disease
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
WO2006050265A2 (en) 2004-10-29 2006-05-11 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
CN101282733A (zh) * 2005-08-03 2008-10-08 莫里亚生物制药公司 脂质结合物在囊性纤维化病中的用途及其应用
US20070162992A1 (en) 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
CA2640614A1 (en) 2006-01-27 2007-08-09 Eastern Virginia Medical School Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
ATE479696T1 (de) * 2006-04-24 2010-09-15 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
WO2007136635A1 (en) * 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
CN101490245B (zh) 2006-06-20 2013-01-16 建新公司 无血清培养基及其在软骨细胞扩增中的用途
EP2106443A4 (en) * 2007-01-05 2010-10-13 Sinai School Medicine ACIDIC CERAMIDASE AND SURVIVAL OF CELLS
AU2008237332A1 (en) 2007-04-06 2008-10-16 Genzyme Corporation Methods of evaluating cells and cell cultures
WO2008148063A1 (en) 2007-05-24 2008-12-04 The Regents Of The University Of California Intranuclear protein transduction through a nucleoside salvage pathway
ES2583527T3 (es) 2007-05-31 2016-09-21 Paradigm Biopharmaceuticals Limited Xilanos sulfatados para el tratamiento o la profilaxis de enfermedades respiratorias
FR2924946B1 (fr) 2007-12-18 2010-02-26 Oreal Utilisation cosmetique de proteines de type ceramidase acide
DE102007063535A1 (de) * 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
JP5721631B2 (ja) * 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
WO2010127355A1 (en) 2009-05-01 2010-11-04 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
HUE046598T2 (hu) 2009-08-28 2020-03-30 Icahn School Med Mount Sinai Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
PT2995306T (pt) 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
SI2504332T2 (sl) 2009-11-27 2021-08-31 Genzyme Corporation Amorfna in kristalinična oblika GENZ 112638 hemitartrata kot inhibitor glukozilceramid sintaze
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
CN103597356A (zh) 2011-05-10 2014-02-19 先进流体逻辑公司 酶浓缩与分析
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
ES2786128T3 (es) * 2012-06-01 2020-10-08 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MX2015012471A (es) 2013-03-14 2016-08-03 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.

Also Published As

Publication number Publication date
CN104582770A (zh) 2015-04-29
LT2854910T (lt) 2020-05-25
EP3679923B1 (en) 2021-08-04
PT2854910T (pt) 2020-05-06
DK2854910T3 (da) 2020-05-04
EP2854910B1 (en) 2020-04-15
CA2874146A1 (en) 2013-12-05
SI2854910T1 (sl) 2020-09-30
US20220202919A1 (en) 2022-06-30
EP2854910A4 (en) 2016-02-24
JP2020050668A (ja) 2020-04-02
JP2015518054A (ja) 2015-06-25
CN104582770B (zh) 2019-01-29
PL2854910T3 (pl) 2020-07-27
JP6369814B2 (ja) 2018-08-08
US9492514B2 (en) 2016-11-15
WO2013181530A1 (en) 2013-12-05
JP2023021305A (ja) 2023-02-10
US20150125439A1 (en) 2015-05-07
ES2786128T3 (es) 2020-10-08
ES2897825T3 (es) 2022-03-02
US20190151424A1 (en) 2019-05-23
US20170020998A1 (en) 2017-01-26
EP2854910A1 (en) 2015-04-08
CA2874146C (en) 2023-03-21
JP2018162303A (ja) 2018-10-18
HRP20200661T1 (hr) 2020-10-30
CN109529028A (zh) 2019-03-29
JP6639574B2 (ja) 2020-02-05
EP3679923A1 (en) 2020-07-15
US10159724B2 (en) 2018-12-25

Similar Documents

Publication Publication Date Title
HK1249861A1 (zh) 治療血紅蛋白病的組合物和方法
EP2854910A4 (en) CERAMID MIRRORS IN THE TREATMENT AND PREVENTION OF INFECTIONS
GB201217296D0 (en) Method of treatment and/or prevention
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1212377A1 (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna /
SG11201504542PA (en) Probiotic strains for the treatment and/or prevention of diarrhœa
IL233875A (en) Preparation and use for the treatment of anal fissures
HK1211983A1 (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions sirna /
HK1206598A1 (en) Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
SI2771016T1 (sl) Primicin in njegove komponente za uporabo pri zdravljenju ali preventivi okužb povzročenimi s specifičnimi patogeni
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
GB201206806D0 (en) Device for the prevention and cure of motion sickness